The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS

QuPath: Open source software for digital pathology image analysis

Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908 · see citing works

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · see citing works

RAS Proteins and Their Regulators in Human Disease

Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · see citing works

GEFs and GAPs: Critical Elements in the Control of Small G Proteins

Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903 · see citing works

RAS oncogenes: the first 30 years

Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · see citing works

RAS oncogenes: weaving a tumorigenic web

Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · see citing works

KRAS ^G12C Inhibition with Sotorasib in Advanced Solid Tumors

Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733 · see citing works

The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants

Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · see citing works

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · see citing works

A Cytoplasmic Protein Stimulates Normal N- <i>ras</i> p21 GTPase, But Does Not Affect Oncogenic Mutants

Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211 · see citing works

Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · see citing works

GTPase-Activating Proteins for Heterotrimeric G Proteins: Regulators of G Protein Signaling (RGS) and RGS-Like Proteins

Ross, E. M., & Wilkie, T. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.795 · Cited by 1,157 · see citing works

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · see citing works

Structure of RGS4 Bound to AlF4−-Activated Giα1: Stabilization of the Transition State for GTP Hydrolysis

Tesmer, J. J. G., Berman, D. M., Gilman, A. G., & Sprang, S. R. (1997) · Cell · doi:10.1016/s0092-8674(00)80204-4 · Cited by 779 · see citing works

Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state

Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works

RGS family members: GTPase-activating proteins for heterotrimeric G-protein α-subunits

Watson, N., Linder, M. E., Druey, K. M., Kehrl, J. H., & Blumer, K. (1996) · Nature · doi:10.1038/383172a0 · Cited by 546 · see citing works

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543 · see citing works

A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems.

Webb, M. (1992) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.89.11.4884 · Cited by 540 · see citing works

Structural Evidence for Feedback Activation by Ras·GTP of the Ras-Specific Nucleotide Exchange Factor SOS

Margarit, S. M., Sondermann, H., Hall, B. E., Nagar, B., Hoelz, A., Pirruccello, M., Bar‐Sagi, D., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00149-1 · Cited by 486 · see citing works

BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition

Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0142 · Cited by 444 · see citing works

Regulators of G-Protein signalling as new central nervous system drug targets

Neubig, R. R., & Siderovski, D. P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd747 · Cited by 403 · see citing works

Drugging RAS: know the enemy

Papke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399 · see citing works

A model for RAS mutation patterns in cancers: finding the sweet spot

Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384 · see citing works

Differential regulation of rasGAP and neurofibromatosis gene product activities

Bollag, G. E., & McCormick, F. P. (1991) · Nature · doi:10.1038/351576a0 · Cited by 341 · see citing works

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324 · see citing works

Purification of ras GTPase activating protein from bovine brain.

Gibbs, W. W., Schaber, M. D., Allard, W. J., Sigal, I. S., & Scolnick, E. M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5026 · Cited by 245 · see citing works

Biochemical and Functional Characterizations of Small GTPase Rheb and TSC2 GAP Activity

Li, Y., Inoki, K., & Guan, K. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.7965-7975.2004 · Cited by 240 · see citing works

Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

Sunaga, N., Shames, D. S., Girard, L., Peyton, M., Larsen, J. E., Imai, H., Soh, J., Sato, M., Yanagitani, N., Kaira, K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0750 · Cited by 175 · see citing works

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer

Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174 · see citing works

The structural basis for the transition from Ras-GTP to Ras-GDP

Hall, B. E., Bar‐Sagi, D., & Nassar, N. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192453199 · Cited by 164 · see citing works

The GTPase-activating protein Rap1GAP uses a catalytic asparagine

Daumke, O., Weyand, M., Chakrabarti, P. P., Vetter, I. R., & Wittinghofer, A. (2004) · Nature · doi:10.1038/nature02505 · Cited by 144 · see citing works

KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis

Rabara, D., Tran, T. H., Dharmaiah, S., Stephens, R. M., McCormick, F., Simanshu, D. K., & Holderfield, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908353116 · Cited by 128 · see citing works

Mechanism of RGS4, a GTPase-activating Protein for G Protein α Subunits

Srinivasa, S. P., Watson, N., Overton, M. C., & Blumer, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1529 · Cited by 121 · see citing works

Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies

Waters, A. M., Ozkan‐Dagliyan, I., Vaseva, A. V., Fer, N. D., Strathern, L. A., Hobbs, G. A., Tessier‐Cloutier, B., Gillette, W., Bagni, R., Whiteley, G., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aao3332 · Cited by 61 · see citing works

14-3-3 protein interacts with and affects the structure of RGS domain of regulator of G protein signaling 3 (RGS3)

Řežábková, L., Bouřa, E., Heřman, P., Večeř, J., Bouřová, L., Šulc, M., Svoboda, P., Obšilová, V., & Obšil, T. (2010) · Journal of Structural Biology · doi:10.1016/j.jsb.2010.03.009 · Cited by 40 · see citing works

The current state of the art and future trends in RAS-targeted cancer therapies

Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549 · see citing works

Pan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth

Kim, D., Herdeis, L., Rudolph, D., Zhao, Y., Böttcher, J., Vides, A., Ayala-Santos, C. I., Pourfarjam, Y., Cuevas-Navarro, A., Xue, J. Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06123-3 · Cited by 534 · see citing works

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science · doi:10.1126/science.adg9652 · Cited by 264 · see citing works

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1420 · Cited by 203 · see citing works

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0158 · Cited by 150 · see citing works

Classification of KRAS -Activating Mutations and the Implications for Therapeutic Intervention

Johnson, C. W., Burkhart, D. L., & Haigis, K. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0035 · Cited by 130 · see citing works

Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors

Lv, X., Lu, X., Cao, J., Luo, Q., Ding, Y., Peng, F., Pataer, A., Lu, D., Han, D., Malmberg, E., et al. (2023) · Science · doi:10.1126/science.abn4180 · Cited by 123 · see citing works

Dynamic regulation of RAS and RAS signaling

Kölch, W., Berta, D., & Rosta, E. (2023) · Biochemical Journal · doi:10.1042/bcj20220234 · Cited by 91 · see citing works

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 87 · see citing works

Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T‐Cells to Activation‐Induced Cell Death in Colorectal Cancer

Liu, H., Liang, Z., Cheng, S., Huang, L., Li, W., Zhou, C., Zheng, X., Li, S., Zeng, Z., & Kang, L. (2023) · Advanced Science · doi:10.1002/advs.202203757 · Cited by 60 · see citing works

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance

Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 59 · see citing works

Pharmacological restoration of GTP hydrolysis by mutant RAS

Cuevas-Navarro, A., Pourfarjam, Y., Hu, F., Rodriguez, D. J., Vides, A., Sang, B., Fan, S., Goldgur, Y., de Stanchina, E., & Lito, P. (2024) · Nature · doi:10.1038/s41586-024-08283-2 · Cited by 47 · see citing works

More to the RAS Story: KRAS ^G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS ^G12C

Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44 · see citing works

KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)

Rosell, R., Codony‐Servat, J., González, J., Santarpía, M., Jain, A. S., Shivamallu, C., Wang, Y., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Nilsson, J. A., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104228 · Cited by 39 · see citing works

D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Zhang, J., Lim, S. M., Yu, M. R., Chen, C., Wang, J., Wang, W., Rui, H., Lu, J., Lü, S., Mok, T. S. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0006 · Cited by 39 · see citing works

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer

Prahallad, A., Weiss, A., Voshol, H., Kerr, G., Sprouffske, K., Yuan, T., Ruddy, D., Meistertzheim, M., Kazic-Legueux, M., Kottarathil, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1127 · Cited by 30 · see citing works

Molecular dynamics simulations for the structure-based drug design: targeting small-GTPases proteins

Parise, A., Cresca, S., & Magistrato, A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2387856 · Cited by 27 · see citing works

Eliminating oncogenic RAS: back to the future at the drawing board

Steffen, C. L., Kaya, P., Schaffner‐Reckinger, E., & Abankwa, D. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221343 · Cited by 23 · see citing works

Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

Ghazi, P. C., O’Toole, K. T., Boggaram, S. S., Scherzer, M. T., Silvis, M. R., Zhang, Y., Jagannathan‐Bogdan, M., Smith, B. D., Lozano, G., Flynn, D. L., et al. (2024) · eLife · doi:10.7554/elife.96992.3 · Cited by 23 · see citing works

Disrupted molecular glue complex drives RAS inhibitor resistance

Sang, B., Ye, L. F., Fu, Z., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Hu, F., Washington, A., Rodriguez, D. J., Vides, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.031 · Cited by 42 · see citing works

KRAS inhibitors, approved

Rosell, R., Aguilar, A., Pedraz‐Valdunciel, C., & CHAIB-OUKADOUR, I. (2021) · Nature Cancer · doi:10.1038/s43018-021-00289-3 · Cited by 23 · see citing works

PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1

Yuan, M., Zhang, C., Chen, S., Ye, S., Liu, H., Ke, H., Huang, J., Liang, G., Yu, R., Hu, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217007 · Cited by 22 · see citing works

Regulation of GTPase function by autophosphorylation

Johnson, C. W., Seo, H., Terrell, E. M., Yang, M.-H., KleinJan, F., Gebregiworgis, T., Gasmi-Seabrook, G. M. C., Geffken, E. A., Lakhani, J., Song, K., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.02.011 · Cited by 21 · see citing works

Mechanism-Based Redesign of GAP to Activate Oncogenic Ras

Berta, D., Gehrke, S., Nyíri, K., Vértessy, B. G., & Rosta, E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04330 · Cited by 21 · see citing works

Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer

Mustafa, M., Abbas, K., Alam, M., Habib, S., Zulfareen, Hasan, G., Islam, S., Shamsi, A., & Hassan, I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1427802 · Cited by 24 · see citing works

Natural products targeting RAS by multiple mechanisms and its therapeutic potential in cancer: An update since 2020

Liu, Y., Chen, J., Li, X., Fan, Y., Peng, C. Y., Ye, X., Wang, Y. A., & Xie, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107577 · Cited by 17 · see citing works

KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

Rosell, R., Lewintre, E. J., Cao, P., Cai, X., Xing, B., Ito, M., Gomez-Vazquez, J. L., Marco-Jordán, M., Fariñas, S. C., Cardona, A. F., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01667-x · Cited by 16 · see citing works

Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

Ghazi, P. C., O’Toole, K. T., Boggaram, S. S., Scherzer, M. T., Silvis, M. R., Zhang, Y., Jagannathan‐Bogdan, M., Smith, B. D., Lozano, G., Flynn, D. L., et al. (2024) · eLife · doi:10.7554/elife.96992 · Cited by 36 · see citing works

RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinoma

Ke, S., Lu, S., Xu, Y., Bai, M., Yu, H., Yin, B., Wang, C., Feng, Z., Li, Z., Huang, J., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01244-9 · Cited by 15 · see citing works

<scp>KRAS</scp> inhibitors: going noncovalent

Drosten, M., & Barbacid, M. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13341 · Cited by 13 · see citing works

Pseudogene UBE2MP1 derived transcript enhances in vitro cell proliferation and apoptosis resistance of hepatocellular carcinoma cells through miR-145-5p/RGS3 axis

Hao, F., Wang, N., Gui, H., Zhang, Y., Wu, Z., & Wang, J. (2022) · Aging · doi:10.18632/aging.204319 · Cited by 13 · see citing works

Synthetic Vulnerabilities in the KRAS Pathway

Román, M., Hwang, E. E., & Sweet-Cordero, A. (2022) · Cancers · doi:10.3390/cancers14122837 · Cited by 12 · see citing works

Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors

Wang, K., Zhang, X., Fan, Y., Zhou, L. F., Duan, Y., Su, L., Sun, Z., Zhang, C., Yang, H., Yuan, W., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103419 · Cited by 13 · see citing works

RGS3 and IL1RAPL1 missense variants implicate defective neurotransmission in early-onset inherited schizophrenias

Kanwal, A., Pardo, J. V., & Naz, S. (2022) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.220070 · Cited by 12 · see citing works

Mechanisms of resistance to active state selective tri-complex RAS inhibitorsPreprint

Sang, B., Ye, L. F., Hu, F., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Fu, Z. Q., Washington, A., Rodriguez, D. J., Vides, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.649345 · Cited by 12 · see citing works

Allosteric modulation of NF1 GAP : Differential distributions of catalytically competent populations in loss‐of‐function and gain‐of‐function mutants

Xu, L., Jang, H., & Nussinov, R. (2025) · Protein Science · doi:10.1002/pro.70042 · Cited by 11 · see citing works

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

Drosten, M., & Barbacid, M. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70149 · Cited by 11 · see citing works

Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy

Yin, G., Lv, G., Zhang, J., Jiang, H., Lai, T., Yang, Y., Ren, Y., Wang, J., Yi, C., Chen, H., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108110 · Cited by 10 · see citing works

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors

Arbour, K. C., & Lito, P. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00562 · Cited by 10 · see citing works

Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance

Jiang, Z., Li, Y., Zhou, X., Wen, J., Zheng, P., & Zhu, W. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117627 · Cited by 9 · see citing works

Fault diagnosis of plunger pump based on audio signal combined with meta-transfer learning

Liu, Y., Dai, Y., & Li, L. (2023) · Journal of Vibration and Control · doi:10.1177/10775463231177338 · Cited by 9 · see citing works

The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer

Lui, K., Cheung, K., Ng, W. W. M., Wang, Y., Au, D. W. H., & Cho, W. C. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211954 · Cited by 8 · see citing works

Real-time monitoring of the reaction of KRAS G12C mutant specific covalent inhibitor by in vitro and in-cell NMR spectroscopy

Zhao, Q., Haga, R., Tamura, S., Shimada, I., & Nishida, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-46623-w · Cited by 8 · see citing works

RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation

Chippalkatti, R., Parisi, B., Kouzi, F., Laurini, C., Fredj, N. B., & Abankwa, D. (2024) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2024.151425 · Cited by 8 · see citing works

Is KRAS (G12C) inhibitor monotherapy for non-small cell lung cancer possible? A review of current literature

Zeng, J., Jiang, W., & Wu, L. (2025) · Journal of Translational Research · doi:10.1080/29947448.2024.2427647 · Cited by 7 · see citing works

Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C

Endres, N., Do, S., Mroue, R. M., Terrett, J. A., Saabye, M., Oh, A., Hunsaker, T., Chan, E., (1471192), J. C. T., Nguyen, L. K., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02272 · Cited by 8 · see citing works

Unraveling the prognostic significance of RGS gene family in gastric cancer and the potential implication of RGS4 in regulating tumor-infiltrating fibroblast

Yang, Y., Xing, S., Luo, X., Guan, L., Lü, Y., Wang, Y.-T., & Feng, W. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1158852 · Cited by 7 · see citing works

The impact of RAS on cell differentiation in health and disease

Duval, C. J., Bottone, S., Schaffner‐Reckinger, E., & Abankwa, D. (2025) · Biochemical Journal · doi:10.1042/bcj20253364 · Cited by 6 · see citing works

Exploring the expression and preliminary function of chicken regulator of G protein signalling 3 (RGS3) gene in follicular development

Shen, M., Li, T., Feng, Y., Chen, Z., Dou, T., Wu, P., Wang, K., Lü, J., & Qu, L. (2022) · British Poultry Science · doi:10.1080/00071668.2022.2071597 · Cited by 6 · see citing works

Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors

Goebel, L., Kirschner, T., Koska, S., Rai, A., Janning, P., Maffini, S., Vatheuer, H., Czodrowski, P., Goody, R. S., Müller, M. P., et al. (2023) · eLife · doi:10.7554/elife.82184 · Cited by 6 · see citing works

Exploring the promise of regulator of G Protein Signaling 20: insights into potential mechanisms and prospects across solid cancers and hematological malignancies

Wang, Y., Qin, J., Sharma, A., Dakal, T. C., Wang, J., Pan, T., Bhushan, R., Chen, P., Setiawan, M. F., Schmidt‐Wolf, I. G. H., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03487-y · Cited by 6 · see citing works

Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy

Jiang, M., Ma, S., Xuan, Y., & Chen, K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117626 · Cited by 6 · see citing works

MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells

Sianoya, A. C., Zuo, Y., Pagba, C. V., Jakubec, J. L., Planque, S. A., Frost, J. A., Medina, P. M. B., & Gorfe, A. A. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-1087 · Cited by 5 · see citing works

GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition

Pfaff, P., & Shokat, K. M. (2026) · Biological Chemistry · doi:10.1515/hsz-2025-0249 · Cited by 5 · see citing works

The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma

Ma, S., Li, K., Wang, R.-R., Qian, J., Fan, Y., Qin, X., Li, M., & Wu, L. (2024) · Clinical Surgical Oncology · doi:10.1016/j.cson.2024.100069 · Cited by 5 · see citing works

KRAS Oncoprotein Signaling in Cancer

Lito, P. (2025) · New England Journal of Medicine · doi:10.1056/nejmcibr2408099 · Cited by 5 · see citing works

Bioreactor in-cell NMR: A powerful tool for observing intracellular biological events

Nishida, N., Zhao, Q., & Shimada, I. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103086 · Cited by 5 · see citing works

Programming the Kinetics of Chemical Communication: Induced Fit vs Conformational Selection

Prévost-Tremblay, C., Vigneault, A., Lauzon, D., & Vallée‐Bélisle, A. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c08597 · Cited by 4 · see citing works

Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics

Zhang, Y., Zeng, F., Peng, S., Chen, Y., Jiang, W., Wang, Z., Li, D., Huang, Z., Qin, H., Yan, H., et al. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2265810 · Cited by 4 · see citing works

Systematic and precise interventions for KRAS-mutant cancers

Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 3 · see citing works

In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRAS G12C-Mutant Non–Small Cell Lung Cancer

Kato, R., Solanki, H. S., Özakıncı, H., Desai, B., Gundlapalli, H., Yang, Y. C., Aronchik, I., Singh, M., Johnson, J., Marusyk, A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3714 · Cited by 3 · see citing works

Drugging mutant KRAS by disrupting binding to effectors and GTP

Cox, A. D., & Der, C. J. (2025) · Nature Cancer · doi:10.1038/s43018-025-00914-5 · Cited by 3 · see citing works

Single-molecule imaging quantifies oncogenic KRAS dynamics for enhanced accuracy of therapeutic efficacy assessment

Yokoi, R., Mori, T., Hirosawa, K. M., Kondo, R., Taguchi, T., Matsuhashi, N., & Suzuki, K. G. N. (2025) · iScience · doi:10.1016/j.isci.2025.113374 · Cited by 3 · see citing works

Filling in the GAPs in understanding RAS

Cox, A. D., & Der, C. J. (2021) · Science · doi:10.1126/science.abl3639 · Cited by 3 · see citing works

Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancerPreprint

Ghazi, P. C., O’Toole, K. T., Boggaram, S. S., Scherzer, M. T., Silvis, M. R., Zhang, Y., Jagannathan‐Bogdan, M., Smith, B. D., Lozano, G., Flynn, D. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.06.579200 · Cited by 3 · see citing works

Functional Analysis of Rare RAS Variants of Unknown Significance

Park, S., Ikegami, M., Kitada, R., Takamochi, K., Suzuki, K., Mano, H., & Kohsaka, S. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0188 · Cited by 2 · see citing works

Whole blood transcriptional signatures of age and survival identified in long life family and integrative longevity omics studies

Li, M., Song, Z., Reed, E. R., Karagiannis, T. T., Andersen, S. L., Brent, M. R., Mateusiak, C., Acharya, S., Jung, W. J., Liao, S., et al. (2026) · GeroScience · doi:10.1007/s11357-025-02090-x · Cited by 2 · see citing works

The heart of the matter: a personal view of Fred Wittinghofer’s contributions to RAS biology and drug design

McCormick, F. P. (2026) · Biological Chemistry · doi:10.1515/hsz-2025-0244 · Cited by 2 · see citing works

Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancerPreprint

Ghazi, P. C., O’Toole, K. T., Boggaram, S. S., Scherzer, M. T., Silvis, M. R., Zhang, Y., Jagannathan‐Bogdan, M., Smith, B. D., Lozano, G., Flynn, D. L., et al. (2024) · eLife · doi:10.7554/elife.96992.2 · Cited by 2 · see citing works

Integrating Multiple Methods to Validate Key Genes Driving the Progression of Breast Ductal Carcinoma In Situ

Zhong, M., Zheng, S., Wen, Y., Zhang, J., Zhang, J., Wang, H., Mo, C., Xu, S., & Chen, X. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100864 · Cited by 1 · see citing works

The impact of K-Ras Gly12 mutants on homeostasis and tumorigenesis in the colonic epithelium

Yang, M. H., Sheth, S., Shui, B., Grabski, I. N., Park, S. S., Galán‐Cobo, A., Irizarri, R., Heymach, J. V., Dow, L. E., & Haigis, K. M. (2026) · Oncogene · doi:10.1038/s41388-026-03771-3 · Cited by 1 · see citing works

BMSCs regulate RGS3 expression in ovarian stromal cells to improve ovarian stromal fibrosis and angiogenic microenvironment in cyclophosphamide-induced premature ovarian failure

Guo, Z., Li, P., Yang, D., Li, J., Sun, X., Qiao, P., Yuan, W., & Du, P. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05017-1 · Cited by 1 · see citing works

A codon-defined translational program promotes RAS-driven cancer progression and drug resistance

Xing, S., Li, J., Ge, L., Shi, Z., Liang, Z., Ren, L., Huang, J., Zheng, Y., Chao, Y., Cheng, J., et al. (2026) · Vita · doi:10.15302/vita.2026.07.0049 · Cited by 1 · see citing works

Redesigned GAP to activate oncogenic GAPPreprint

Berta, D., Gehrke, S., Nyíri, K., Vértessy, B. G., & Rosta, E. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2022-ttt09-v2 · Cited by 1 · see citing works

Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancerPreprint

Ghazi, P. C., O’Toole, K. T., Boggaram, S. S., Scherzer, M. T., Silvis, M. R., Zhang, Y., Jagannathan‐Bogdan, M., Smith, B. D., Lozano, G., Flynn, D. L., et al. (2024) · eLife · doi:10.7554/elife.96992.1 · Cited by 1 · see citing works

Transcriptional landscapes and signaling pathways of chloroquine-treated Esophageal squamous cell carcinomaPreprint

Wang, W., & Qian, Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.19.504517

Effects of Forkhead Box D1 (FOXD1) on renal cell carcinomaPreprint

Wang, M., Li, N., Qin, J., & Hu, A. K. (2022) · Research Square · doi:10.21203/rs.3.rs-1974991/v1

Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23310275

Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23310275.v1

Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23641387

Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23641387.v1

РОЛЬ ЭКОЛОГИЧЕСКИХ ФАКТОРОВ ВО ВЗАИМОДЕЙСТВИИ С ГЕНЕТИЧЕСКИМИ МАРКЕРАМИ В ПОКАЗАТЕЛЯХ ЗДОРОВЬЯ

Rakhimbekova, F., Рыспамбетов, Ж. Ж., Anapiyayev, B. B., & Orazgaliyeva, M. (2023) · Farmaciâ Kazahstana · doi:10.53511/pharmkaz.2023.26.50.021

Data from CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Prahallad, A., Weiss, A., Voshol, H., Kerr, G., Sprouffske, K., Yuan, T. L., Ruddy, D. A., Meistertzheim, M., Kazic-Legueux, M., Kottarathil, T., et al. (2023) · doi:10.1158/0008-5472.c.6982749

Data from CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Prahallad, A., Weiss, A., Voshol, H., Kerr, G., Sprouffske, K., Yuan, T. L., Ruddy, D. A., Meistertzheim, M., Kazic-Legueux, M., Kottarathil, T., et al. (2023) · doi:10.1158/0008-5472.c.6982749.v1

Gene Expression Profiling to Predict Prognostic Biomarkers for Relapse in Multiple Myeloma

Elahi, S., & Fazal, S. (2024) · Advancements in Life Sciences · doi:10.62940/als.v11i2.1900

Exploring the biological behavior differences between retroperitoneal and non-retroperitoneal liposarcomas

Xi, Z., Zhuang, A., Li, X., Ming, T. M., Cheng, Y., Zhang, C., Xie, F., Wang, Y., Yan, G., Zheng, J., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34878

eLife Assessment: Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

Evans, R. (2024) · eLife · doi:10.7554/elife.96992.2.sa2

Reviewer #2 (Public Review): Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

(2024) · eLife · doi:10.7554/elife.96992.2.sa1

Author response: Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

Ghazi, P. C., O’Toole, K. T., Boggaram, S. S., Scherzer, M. T., Silvis, M. R., Zhang, Y., Jagannathan‐Bogdan, M., Smith, B. D., Lozano, G., Flynn, D. L., et al. (2024) · eLife · doi:10.7554/elife.96992.2.sa0

The emergence of pan-KRAS drugs

McConnell, D. B., & Kraut, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00019-x

Cooperativity between Ras pathway mutations in colonic tumorigenesisPreprint

Johnson, C. W., Idelevich, A., Shui, B., Tisdale, A. W., O’Donoghue, E., Cook, J., Hull, S., Yang, M. H., Sheth, S., Terrell, E. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.05.673994

eIF2B Selectively Anchors and Activates Mutant KRASPreprint

Kim, H., Diao, S., Cho, K., Lee, H.-R., Liu, J., Egea, P. F., Pantsar, T., Kurki, M., Ghaddar, N., Wang, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.10.686860

Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

Rosell, R., Lewintre, E. J., Cao, P., Cai, X., Xing, B., Ito, M., Gomez-Vazquez, J. L., Marco-Jordán, M., Fariñas, S. C., Cardona, A. F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26027462

Design, Synthesis, and Biological Evaluation of Novel 1 H -Imidazo[4,5-g]quinazoline-Based SOS1::KRAS G12C Inhibitors in Colorectal Cancer Cells

Huang, X., Huang, J., Hong, Q., Ou, X., Li, R., Zong, M., Lu, T., Zhu, Y., Hao, H., Wu, S., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00754

The Neomorphic Chemistry of KRAS Autophosphorylation Is Dynamically Regulated by Active Site Conformation

Johnson, C. W., Oladimeji, R., O’Donohue, E., & Haigis, K. M. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00157

Unlocking drug sensitivity in KRAS

MingCong, L. I., YueSong, Z. H. O. U., Qiao, T. D., QingLin, B. A. I., & Li, C. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0279

RGS19 drives tumor progression and immunosuppression in clear cell renal cell carcinoma by modulating CAMs and EMT

Li, Z., Lian, Z., Ma, K., 宋伟航, Xue, X., & Li, L. (2026) · World Journal of Surgical Oncology · doi:10.1186/s12957-026-04355-x

Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors

Zhu, Y., Zhang, C., Li, M., Ai, L., Xu, F., Yu, Y., Yu, S., Xu, X., Liu, Q., Zhu, M., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03838-1

RGS Family Remodeling in Breast Cancer: A Meta‐Analysis and Multi‐Omics Profiling of Prognostic Biomarkers

Mirzaei, Z., Moghaddam, M. M., Barati, T., Ebrahimi, A., & Khaniani, M. S. (2026) · Cancer Medicine · doi:10.1002/cam4.72115

A High-Throughput Assay to Identify Specific Nascent Chain InhibitorsPreprint

Fischer, P. D., & Hiller, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.03.749102

Drugging mutant KRAS by disrupting binding to effectors and GTP

Cox, A. D., & Der, C. J. (2025) · Nature Cancer · doi:10.1038/s43018-025-00914-5 · Cited by 3 · see citing works

Onkogén KRAS mutánsok működésének helyreállítását célzó GAP fehérje mutánsok nyomában: In the wake of GAP protein mutants to repair the malfunction of oncogenic KRAS mutants

Ildikó, S., Nyíri, K., & Beáta, V. G. (2021) · Nemzetközi Vegyészkonferencia

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works

Abstract LB-071: Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Lito, P., Solomon, M., Hansen, R., Li, L., & Rosen, N. X. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-lb-071

A06 Tri-complex Inhibitors of the Oncogenic, GTP-Bound Form of KRASG12C Overcome RTK-Mediated Escape Mechanisms and Drive Tumor Regressions in Preclinical Models of NSCLC

Nichols, R., Schulze, C. J., Bermingham, A., Choy, T. J., Cregg, J., Kiss, G., Marquez, A., Reyes, D., Saldajeno-Concar, M., Weller, C. E., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.035 · Cited by 23 · see citing works